

# Competitive Memory training in patients with auditory verbal hallucinations: a randomized con-trolled trial.

Published: 14-12-2007

Last updated: 10-05-2024

The aim of this study is to determine whether the treatment is effective in reducing symptoms in patients suffering from AVH\*s.

<b>Ethical review</b>	Approved WMO
<b>Status</b>	Recruiting
<b>Health condition type</b>	Schizophrenia and other psychotic disorders
<b>Study type</b>	Interventional

## Summary

### ID

NL-OMON31865

### Source

ToetsingOnline

### Brief title

COMET

### Condition

- Schizophrenia and other psychotic disorders

### Synonym

auditory verbal hallucinations, hearing voices

### Research involving

Human

### Sponsors and support

**Primary sponsor:** Parnassia (Den Haag)

**Source(s) of monetary or material Support:** deelnemende instellingen

## Intervention

**Keyword:** Cognitive therapy, Hallucinations, Schizophrenia

## Outcome measures

### Primary outcome

Primary study parameters/outcome of the study:

PSYRATS / AHRs (voices)

### Secondary outcome

SCRS (social comparison rating scale)

BDI (depression)

BAI (anxiety)

PUL (self-efficacy)

BCIS (insight)

PSc (power differential scale)

SERS (self esteem)

MCQ30 (metacognitions)

A motivational inventory

A neuropsychological test measuring memory bias

Emotional stroop (attentional bias)

## Study description

### Background summary

Auditory Verbal Hallucinations (voices) are one of the most persistent and distressing symptoms in patients suffering from schizophrenia. AVH\*s are also commonly found in other psychiatric disorders. Mostly they are resistant to medication en therefore they are often responsible for co-morbid symptoms such

as depression and anxiety. Training the memory bias shows hopeful re-sults in treating patients with AVH\*s.

## **Study objective**

The aim of this study is to determine whether the treatment is effective in reducing symptoms in patients suffering from AVH\*s.

## **Study design**

Following a recent pilot a randomised clinical trial is being started. The effectiveness of this new treatment is being evaluated in patients diagnosed with schizophrenia, schizo-affective disorder or psychotic disorder NOS experiencing severe distress from their auditory verbal hallucinations. Results are being measured by means of inventories and neuropsychological tests.

There will be two conditions:

1) Patients who are in the experimental group receive a 9-session program following the COMET-protocol. Their treatment as usual (TAU) will be continued during the program

2) Patients who are in the control group receive treatment as usual (TAU). Usually this con-sists of sessions with an outpatient therapist and/or a psychiatrist.

Patients will be subjected to tests and inventories at the start, after 10 weeks and after 18 weeks.

## **Intervention**

The experimental group will have 9 sessions of competitive memory training; the control group is a waiting list

## **Study burden and risks**

No burden, no documented risks and adverse events.

## **Contacts**

### **Public**

Parnassia (Den Haag)

Oude Haagweg 353

2552 ES Den Haag

Nederland

### **Scientific**

Parnassia (Den Haag)

Oude Haagweg 353  
2552 ES Den Haag  
Nederland

## Trial sites

### Listed location countries

Netherlands

## Eligibility criteria

### Age

Adults (18-64 years)

Elderly (65 years and older)

### Inclusion criteria

Patients suffering from persistent auditory verbal hallucinations in the age 18 to 65. Three particular items of the PSYRATS (Haddock et al. 1999) will be used to screen patients. These items measure frequency of voices (item 1) intensity of distress (item 9) and disturbance of daily functioning (item 10). Patients with results higher than 3 will be included. We defined the hallucinations \*persistent\* if they still cause distress despite the administration of two different types of antipsychotic medication.

### Exclusion criteria

severe abuse of substances, insufficient knowledge and practice of Dutch language.

## Study design

### Design

Study type:	Interventional
Intervention model:	Parallel
Allocation:	Randomized controlled trial

Masking: Single blinded (masking used)

**Primary purpose:** Treatment

## Recruitment

NL

Recruitment status: Recruiting

Start date (anticipated): 01-04-2008

Enrollment: 128

Type: Actual

## Medical products/devices used

Registration: No

## Ethics review

Approved WMO

Date: 14-12-2007

Application type: First submission

Review commission: METIGG: Medisch Ethische Toetsingscommissie Instellingen Geestelijke Gezondheidszorg (Utrecht)

## Study registrations

### Followed up by the following (possibly more current) registration

No registrations found.

### Other (possibly less up-to-date) registrations in this register

No registrations found.

## In other registers

**Register**

CCMO

**ID**

NL19896.097.07